Sanofi (SNY) issued the following statement regarding rule 2.12 of the takeover rules: "Sanofi S.A. confirms that any offer for Horizon Therapeutics plc, if made by Sanofi, will be solely in cash. There is no certainty that any offer will be made, nor as to the terms on which any such offer may be made, if forthcoming."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNY:
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
- Sanofi reports Phase II/III study results for acoziborole published in Lancet
- Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi
- Horizon Therapeutics confirms preliminary deal talks with Amgen, Janssen, Sanofi